Treatment Of Cd30 Lymphoproliferative Disorders

CD30+ cutaneous lymphoproliferative disorders include LyP presenting with chronic, recurrent, and self-healing skin eruptions and CD30+ LTCL.87 Their common phenotypic hallmark is the CD30+ T lymphocyte that morphologically resembles ReedSternberg cells. Reported treatment modalities are doxycycline, PUVA, NB-UVB, methotrexate, INF-a, topical steroid and bexarotene formulations, and radiation.88-91 However, none of these treatments alter the natural course of disease; therefore, the short-term benefits should be weighed against the potential harmful side effects. Observation in patients with few lesions is recommended, whereas in patients with more disseminated disease low-dose methotrexate or UV light treatment might be effective in clearing disease.92

Primary cutaneous CD30+ LTCL presenting with solitary or localized cutaneous nodules appear to have a favorable prognosis, as confirmed in several studies.93 Spot radiation for solitary or localized lesions is the preferred treatment, with systemic chemotherapy reserved for cases with large tumor burden and/or extracuta-neous involvement.9495 Therapy regimens include dox-orubicin-based (doxorubicin with CHOP or CHOP-like) chemotherapy, INF-a, or oral bexarotene.

0 0

Post a comment